Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegade: Infliximab Induction for HCV Genotype 1
NCT00237484Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2005
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in hepatitis C (HCV), sponsored by Merck & Co.. Started Jul 2005; status: completed.
02
Drugs
infliximab
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00237484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00237484.